Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 574 participants.

Also called NCT05554822

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 574 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05554822
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05554822. Randomized; no masking; primary purpose treatment. Start 2021-06-14 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
Acronym
ARMYDA-AMULET
Condition
Left Atrial Appendage Occlusion
Condition
Antiplatelet Therapy
Intervention (Drug)
Aspirin 100mg
Intervention (Drug)
Aspirin 100 mg OD plus clopidogrel 75 mg OD
Lead sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita (class: other)
Collaborator
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct05554822
Content hash
07580171a59f6bf4824fd82f9baea15653920e002e146b8fc54c613229da56c1